Norroy Bioscience CO., LTD

CN EN

About Norroy

Our Technology

Nuclear Equipment

Press Release

Release News

Contact

Innovative Radiopharmaceutical Development

Dedicated to addressing the unmet clinical needs in the field of refractory tumors such as urinary and digestive tract tumors
Focus on new drugs and mature targets

A rich R&D pipeline with multiple independent research and development and innovative drugs with global intellectual property rights
Improve industry innovation capabilities

Accelerate to bring more innovative therapies to patients

Innovative Radiopharmaceutical Development

Dedicated to addressing the unmet clinical needs in the field of refractory tumors such as urinary and digestive tract tumors
Focus on new drugs and mature targets

A rich R&D pipeline with multiple independent research and development and innovative drugs with global intellectual property rights
Improve industry innovation capabilities

Accelerate to bring more innovative therapies to patients

POSITION：HOME > Our Technology >Technology Platform >Technology platform of clinical transformation

Technology platform of Clinical transformation
————

Norroy has an independent platform for proprietary technology. This platform integrates nuclear medicine technology, high-throughput screening, clinical transformation, and quantitative pharmacology of tumor drugs to form a cohesive unit. It serves as the core support for innovation and research within Norroy's system, encompassing small molecules, antibodies, peptides, and various other types of drugs. Through this platform, Norroy can efficiently identify potential drug candidates, significantly enhance the success rate of drug screening and transformation, effectively expedite the progression of clinical trials, and establish a robust foundation for the company's future launch of more innovative theranostic drugs.

Technology platform of Linker for nuclear drugs

The nuclear drug linker technology, developed and designed by Norroy, facilitates efficient and stable drug-radioisotope binding through the distinctive molecular design and advanced synthesis methods.

Innovative platform for high-throughput screening and clinical transformation of nuclear drugs

Based on the rich experience of Norroy team in radiolabeling and the advantages of molecular imaging technology, through large-scale screening and early clinical research, we can find and validate candidate drugs faster, and prepare for clinical trials.

Pharmacological development platform for quantitative research of cancer drugs

Study drug in the body's metabolism, pharmacodynamics and pharmacokinetics, to optimize the dose of drug design and treatment plan.